How the GERD Diagnosis and Reflux Testing Actually Work

For most people with classic heartburn and regurgitation and no warning signs, the American College of Gastroenterology's 2022 guideline does not begin with a camera or a probe. It begins with an eight-week trial of a once-daily proton pump inhibitor (PPI) taken before a meal, because that approach treats the most likely problem and gathers diagnostic information at the same time. Objective testing, meaning upper endoscopy and ambulatory reflux monitoring, is held in reserve for symptoms that do not fit the pattern, do not respond, or must be confirmed before surgery. A good response supports the diagnosis; a poor one is a signal to look harder rather than to keep escalating acid suppression.

Why the guideline starts with a treatment, not a test

Gastroesophageal reflux disease is common, and the classic presentation of heartburn plus regurgitation without alarm features is recognizable enough that starting therapy is reasonable and cost-effective. The ACG guideline recommends the eight-week empiric PPI course as the first step for exactly this group.

The reason this is framed as a therapeutic trial rather than a diagnostic test is honesty about its accuracy. When response to a PPI is measured against endoscopy and pH monitoring, the pooled sensitivity is about 78% and the specificity only around 54%. In plain terms, a PPI can relieve symptoms that were never caused by acid, and it can fail to relieve symptoms that were. That is why the guideline treats improvement as supportive evidence, not proof, and why chasing a partial response with ever-higher doses is discouraged. A frequently cited multicenter study found that only about 21% of patients with persistent heartburn on PPIs actually had truly refractory GERD. The rest had something else.

The alarm symptoms that change the plan

Certain features move endoscopy to the front of the line. Difficulty swallowing, painful swallowing, unintentional weight loss, gastrointestinal bleeding or iron-deficiency anemia, and a palpable mass all warrant upper endoscopy first, because they can signal a stricture, a cancer, or another structural problem that a PPI would only mask. Endoscopy is also appropriate for people with several risk factors for Barrett's esophagus, the precancerous change that chronic reflux can produce.

Timing matters here in a way that is easy to get wrong. The guideline advises performing endoscopy after PPIs have been stopped for two weeks, and up to four when feasible, so that erosive esophagitis is not healed out of view and so that eosinophilic esophagitis, an allergic condition that mimics reflux, is not missed. Endoscopy that finds erosive disease or Barrett's confirms GERD outright. A normal endoscopy, which is the more common result, rules out the dangerous look-alikes but does not by itself exclude reflux.

When objective reflux testing is required

Ambulatory reflux monitoring is the test that actually measures acid in the esophagus, and the guideline calls for it in defined situations: when the diagnosis remains unproven after an inconclusive trial, when symptoms persist despite treatment, and before any antireflux surgery or endoscopic procedure. How the test is run depends on the question being asked.

If GERD has never been objectively established, monitoring is done off PPI therapy to see whether pathologic reflux exists at all. If GERD is already documented and the question is why symptoms persist, monitoring is done on therapy, often with impedance, to capture weakly acidic and nonacid reflux that a pH sensor alone would miss. A wireless capsule clipped to the esophageal lining can record for 48 to 96 hours and is generally more comfortable, while a thin transnasal catheter is needed when impedance is required.

The numbers that adjudicate these studies come from the Lyon Consensus, the international framework the field now uses. Acid exposure time, the fraction of the day the esophagus sits below pH 4, tells most of the story: above 6% is conclusive for pathologic reflux, below 4% is normal, and 4% to 6% is borderline and needs supporting evidence. In that gray zone, adjunctive metrics help, since a low mean nocturnal baseline impedance points toward reflux disease, while a strong association between reflux episodes and a patient's own symptoms raises confidence that the two are linked.

When the testing overturns the diagnosis

This is where reflux testing earns its keep. When acid exposure is normal but reflux events still track tightly with symptoms, the diagnosis shifts to reflux hypersensitivity. When acid exposure is normal and there is no symptom association, the label is functional heartburn, an esophageal pain-processing disorder rather than an acid problem. Neither responds well to more acid suppression, and identifying them redirects care toward the treatments that actually help.

High-resolution manometry plays a supporting role in this workup. It is not a test for GERD, but it is recommended before antireflux surgery, in part to rule out achalasia, a motility disorder that can masquerade as reflux and would be made worse by a fundoplication. The sequence of empiric therapy, then endoscopy when warranted, then physiologic testing before anything irreversible, is designed to keep patients from being committed to surgery for a disease they do not have.

What this means if your reflux persists

The practical takeaway is that persistent symptoms on a PPI are a reason to test, not automatically a reason to escalate the dose. Objective measurement can confirm reflux, reclassify it, or point the search in a new direction, and each of those answers changes what should happen next. This article is educational and not a substitute for individual medical advice.